Elite Pharmaceuticals Inc
ELTP- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001053369
In the last 90 days, Elite Pharmaceuticals Inc insiders filed 2 open-market purchases and 0 sales; 1 institution reported holding it in 13F filings for Q2 2026, worth $365 in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 12:16 PM ET
Revenue flow, FY2026
Where the revenue went in FY2026, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jun 29, 2026 | Jun 30, 2025 | Jul 1, 2024 | Jun 29, 2023 | Jun 29, 2022 |
| Revenue | $148.9M | $84.0M | $56.6M | $34.2M | $32.3M |
| Cost of revenue | $73.8M | $44.0M | $30.3M | $17.6M | $17.5M |
| Gross profit | $75.0M | $40.1M | $26.4M | $16.6M | $14.8M |
| Operating expenses | $25.9M | $20.5M | $15.6M | $12.9M | $9.72M |
| Research and development | $5.74M | $7.96M | $6.88M | $6.20M | $4.05M |
| Selling, general and administrative | $17.6M | $9.00M | $7.15M | $5.12M | $4.46M |
| Operating income | $49.1M | $19.6M | $10.8M | $3.68M | $5.07M |
| Interest expense | $111.4K | $128.2K | $588.6K | $1.11M | $191.8K |
| Income tax | $11.9M | $4.26M | -$19.6M | $424.0K | -$1.74M |
| Net income | $44.9M | -$4.31M | $20.1M | $3.56M | $8.90M |
| EPS, basic | $0.04 | $0.00 | $0.02 | $0.00 | $0.01 |
| EPS, diluted | $0.03 | $0.00 | $0.02 | $0.00 | $0.01 |
| Weighted shares, basic | 1.07B | 1.07B | 1.02B | 1.01B | 1.01B |
| Weighted shares, diluted | 1.14B | 1.07B | 1.02B | 1.01B | 1.01B |
| Margins and growth | |||||
| Gross margin | 50.4% | 47.7% | 46.5% | 48.6% | 45.9% |
| Operating margin | 33.0% | 23.3% | 19.1% | 10.8% | 15.7% |
| Net margin | 30.1% | -5.1% | 35.5% | 10.4% | 27.6% |
| Revenue growth, year over year | +77.1% | +48.4% | +65.8% | +5.9% | +27.1% |
| Net income growth, year over year | – | −121.5% | +464.6% | −60.0% | +74.9% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jun 29, 2026 | Jun 30, 2025 | Jul 1, 2024 | Jun 29, 2023 | Jun 29, 2022 |
| Cash and equivalents | $29.8M | $11.3M | $7.11M | $7.83M | $8.54M |
| Accounts receivable | $59.7M | $29.2M | $19.5M | $3.09M | $3.06M |
| Inventory | $21.3M | $16.2M | $12.9M | $9.55M | $6.74M |
| Total current assets | $112.1M | $57.7M | $40.0M | $21.5M | $18.9M |
| Property, plant and equipment | $10.2M | $10.3M | $10.2M | $10.4M | $5.95M |
| Intangible assets | $4.79M | $5.64M | $6.34M | $6.34M | $6.63M |
| Total assets | $138.3M | $96.4M | $83.7M | $40.9M | $35.1M |
| Accounts payable | $6.05M | $2.96M | $2.71M | $2.45M | $1.43M |
| Total current liabilities | $17.4M | $11.8M | $13.0M | $7.83M | $6.69M |
| Long-term debt | – | – | – | – | $1.36M |
| Total liabilities | $39.4M | $42.9M | $26.1M | $11.9M | $9.93M |
| Shareholders' equity | $98.9M | $53.5M | $57.6M | $29.0M | $25.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jun 29, 2026 | Jun 30, 2025 | Jul 1, 2024 | Jun 29, 2023 | Jun 29, 2022 |
| Operating cash flow | $23.7M | $7.46M | -$3.28M | $3.34M | $6.51M |
| Capital expenditures | $925.6K | $1.63M | $809.7K | $5.74M | – |
| Free cash flow | $22.8M | $5.83M | -$4.09M | -$2.40M | – |
| Depreciation and amortization | $1.07M | $1.23M | $1.32M | $1.28M | $1.21M |
| Stock-based compensation | $176.5K | $227.6K | $159.9K | $39.3K | $14.4K |
| Investing cash flow | -$925.6K | -$2.40M | -$809.7K | -$5.74M | -$498.6K |
| Financing cash flow | -$4.32M | -$825.7K | $3.39M | $1.70M | -$667.1K |
| Net change in cash | $18.5M | $4.23M | -$705.6K | -$695.7K | – |
| Ratio | |||||
| Stock-based compensation, % of revenue | 0.1% | 0.3% | 0.3% | 0.1% | 0.0% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 13, 2026 | 1.08B | +0.6% | SEC |
| Jun 27, 2026 | 1.08B | +0.8% | SEC |
| Feb 13, 2026 | 1.08B | +0.8% | SEC |
| Nov 14, 2025 | 1.07B | +0.6% | SEC |
| Aug 14, 2025 | 1.07B | +0.3% | SEC |
| Jun 27, 2025 | 1.07B | 0.0% | SEC |
| Feb 13, 2025 | 1.07B | +5.0% | SEC |
| Nov 14, 2024 | 1.07B | +5.4% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.